356 related articles for article (PubMed ID: 10557063)
1. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
2. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
Hazlehurst LA; Valkov N; Wisner L; Storey JA; Boulware D; Sullivan DM; Dalton WS
Blood; 2001 Sep; 98(6):1897-903. PubMed ID: 11535527
[TBL] [Abstract][Full Text] [Related]
3. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
4. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
5. MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison.
Xie CY; Zhu H; Lin LP; Miao ZH; Geng MY; Cai YJ; Chen Y; Zhao HJ; Luo HB; Zhang XW; Fan LM; Shen YM; Ding J
Mol Cancer Ther; 2007 Nov; 6(11):3059-70. PubMed ID: 18025289
[TBL] [Abstract][Full Text] [Related]
6. A novel use for the comet assay: detection of topoisomerase II inhibitors.
Salti GI; Das Gupta TK; Constantinou AI
Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
[TBL] [Abstract][Full Text] [Related]
7. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
8. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10(7):1177-80. PubMed ID: 8683999
[TBL] [Abstract][Full Text] [Related]
10. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
Kurz EU; Wilson SE; Leader KB; Sampey BP; Allan WP; Yalowich JC; Kroll DJ
Mol Cancer Ther; 2001 Dec; 1(2):121-31. PubMed ID: 12467229
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Gieseler F; Glasmacher A; Kämpfe D; Wandt H; Nuessler V; Valsamas S; Kunze J; Wilms K
Leukemia; 1996 Jul; 10 Suppl 3():S46-S49. PubMed ID: 8656700
[TBL] [Abstract][Full Text] [Related]
13. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
Aoyagi Y; Kobunai T; Utsugi T; Wierzba K; Yamada Y
Jpn J Cancer Res; 2000 May; 91(5):543-50. PubMed ID: 10835500
[TBL] [Abstract][Full Text] [Related]
15. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
16. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.
Chikamori K; Hill JE; Grabowski DR; Zarkhin E; Grozav AG; Vaziri SA; Wang J; Gudkov AV; Rybicki LR; Bukowski RM; Yen A; Tanimoto M; Ganapathi MK; Ganapathi R
Leukemia; 2006 Oct; 20(10):1809-18. PubMed ID: 16932348
[TBL] [Abstract][Full Text] [Related]
18. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
19. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
Suzuki H; Tarumoto Y; Ohsawa M
Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
